Immunoliposomes: a new therapeutic option to treat SynGAP1-associated epilepsy
The blood-brain barrier (BBB) hinders the uptake of most drugs into the brain. Thus, active processes, physiologically necessary for nutrient uptake, like receptor-mediated transcytosis have become popular targets for drug transport. One such receptor is the transferrin receptor 1 (TfR), being highl...
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
September 2025
|
| In: |
European journal of pharmaceutics and biopharmaceutics
Year: 2025, Volume: 214, Pages: 1-11 |
| ISSN: | 1873-3441 |
| DOI: | 10.1016/j.ejpb.2025.114799 |
| Online Access: | Verlag, kostenfrei, Volltext: https://doi.org/10.1016/j.ejpb.2025.114799 Verlag, kostenfrei, Volltext: https://www.sciencedirect.com/science/article/pii/S0939641125001766 
|
| Author Notes: | K. Wienken, A. Mazur, B. Gericke, S. Petralla, L. Wagner, O. Seifert, R.E. Kontermann, G. Fricker |
| Summary: | The blood-brain barrier (BBB) hinders the uptake of most drugs into the brain. Thus, active processes, physiologically necessary for nutrient uptake, like receptor-mediated transcytosis have become popular targets for drug transport. One such receptor is the transferrin receptor 1 (TfR), being highly expressed at the BBB. Immunoliposomes targeting the TfR were loaded with rosuvastatin to improve the therapy of SynGAP1-associated epilepsy. The rational of using rosuvastatin is based on its function downregulating the Ras-Raf-MEK-ERK pathway, which is upregulated in excitatory neurons in patients with SynGAP1-related disorders. However, rosuvastatin shows poor BBB permeability. Therefore, immunoliposomes decorated with anti-TfR antibody Ox26 and its single-chain variable fragment (scFv) were prepared and characterized. Immunoliposomes could be prepared reproducibly with a size of about 125 nm, were not hemolytically active and showed colloidal stability in plasma for 2 h. They exhibited a high uptake into endothelial cells which was not altered in presence of the natural ligand transferrin. In vivo application of fluorescently labeled immunoliposomes demonstrated a long plasma half-life and accumulation in brain capillaries. In comparison to unmodified liposomes, Ox26- and scFv-immunoliposomes showed a 2.8- and 2.5-fold improved transfer of rosuvastatin into brain tissue, suggesting successful passage of the BBB. |
|---|---|
| Item Description: | Online verfügbar: 19. Juni 2025, Version des Artikels 5. Juli 2025 Gesehen am 18.11.2025 |
| Physical Description: | Online Resource |
| ISSN: | 1873-3441 |
| DOI: | 10.1016/j.ejpb.2025.114799 |